MedTrace Logo

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

NCT01561807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2016-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.

Conditions

  • Influenza Virus

Interventions

DRUG

VX-787

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Jose Trevejo, MD, PhD · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561807 on ClinicalTrials.gov